8-K
filed February 14, 2023, 6:59 PM ET
ticker ELTP
CIK 0001053369
earnings
confidence high
sentiment positive
materiality 0.50
Elite Pharma Q3 revenue $9.3M (+3% YoY), net income $2.96M
ELITE PHARMACEUTICALS INC /NV/
2023-Q3 EPS reported
$0.01
revenue$25,513,551
- Q3 FY2023 revenue $9.3M, up 3% from prior year; operating profit $2.0M.
- Net income for Q3 was $2.96M; nine-month net income $4.79M.
- Nine-month revenue $25.5M (+4% YoY); operating profit $4.1M (down $0.1M).
- Growth driven by generic immediate-release and extended-release Adderall.
- Conference call set for Feb 15, 2023 at 11:30 AM EST to discuss results.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ELITE PHARMACEUTICALS INC /NV/ reported the nine-month period ended December 31, 2022 results: revenue $25.5 million, net income $4.79 million.
- Period
- the nine-month period ended December 31, 2022
- Revenue
- $25.5 million
- Net income
- $4.79 million
- Result
- reported results
Exact text from the filing
Consolidated revenues for the nine-month period ended December 31, 2022, were $25.5 million, an increase of $0.90 million or 4% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $4.1 million, a decrease of $0.10 million from the comparable period of the prior year, and net income was $4.79 million.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ELITE PHARMACEUTICALS INC /NV/ reported the third quarter of fiscal year 2023 ended December 31, 2022 results: revenue $9.3 million, net income $2.96 million.
- Period
- the third quarter of fiscal year 2023 ended December 31, 2022
- Revenue
- $9.3 million
- Net income
- $2.96 million
- Result
- reported results
Exact text from the filing
Consolidated revenues for the three-month period ended December 31, 2022, were $9.3 million, an increase of $0.30 million or 3% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $2.0 million, an increase of $0.12 million from the prior year’s comparable period, and net income was $2.96 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.